Stockscreener 앱 받기
14.21
3.45%
-0.72
전일 마감가:
$14.93
열려 있는:
$15.1
하루 거래량:
14,216
Relative Volume:
0.15
시가총액:
$149.80M
수익:
$88.50M
순이익/손실:
$-35.27M
주가수익비율:
-4.3121
EPS:
-3.2954
순현금흐름:
$-23.70M
1주 성능:
+3.41%
1개월 성능:
+35.48%
6개월 성능:
+83.16%
1년 성능:
+110.38%
1일 변동 폭
$14.24
$15.10
1주일 범위
$13.90
$15.44
52주 변동 폭
$5.00
$20.21
바이오데식스 Stock (BDSX) Company Profile
명칭
Biodesix Inc
전화
303-417-0500
주소
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX vs TMO, DHR, IDXX, WAT, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
14.46 | 154.61M | 88.50M | -35.27M | -23.70M | -3.2954 |
TMO
Thermo Fisher Scientific Inc
|
448.14 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.71 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.23 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
341.93 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.16 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
바이오데식스 Stock (BDSX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-05-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-09-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-26 | 개시 | Craig Hallum | Buy |
| 2024-05-13 | 개시 | TD Cowen | Buy |
| 2024-05-03 | 개시 | Lake Street | Buy |
| 2021-11-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | 개시 | BTIG Research | Buy |
| 2020-11-23 | 개시 | Canaccord Genuity | Buy |
| 2020-11-23 | 개시 | Morgan Stanley | Overweight |
| 2020-11-23 | 개시 | William Blair | Outperform |
모두보기
바이오데식스 주식(BDSX)의 최신 뉴스
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade - Zacks Investment Research
Canaccord Lifts PT on Biodesix (BDSX) on Raised Revenue Assumptions - Insider Monkey
BDSX Stock Price, Quote & Chart | BIODESIX INC (NASDAQ:BDSX) - ChartMill
Biodesix (NASDAQ: BDSX) registers 375,000 shares for Perceptive resale - Stock Titan
Biodesix meets investors in Minneapolis, Chicago and Dana Point - Stock Titan
Biodesix to Participate in Upcoming Investor Conferences - Caledonian Record
Biodesix shareholders elect directors and approve executive compensation By Investing.com - Investing.com Australia
Biodesix shareholders elect directors and approve executive compensation - Investing.com
Biodesix Shareholders Approve Directors and Governance Measures - TipRanks
Biodesix (NASDAQ: BDSX) holders back directors, pay and KPMG auditor - Stock Titan
Perceptive entities disclose 4.6% holding in Biodesix (NASDAQ: BDSX) - Stock Titan
Biodesix BDSX Q2 2025 Earnings Call Transcript - AOL.com
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy - The Manila Times
Blood test for lung nodules gets real-world spotlight at ATS 2026 - Stock Titan
Biodesix to present new real-world data on Nodify Lung testing at ATS 2026, highlighting clinical and economic benefits. - Pluang
Does Biodesix (BDSX) have the potential to rally 103.33% as Wall Street analysts expect? - MSN
Biodesix (NASDAQ: BDSX) holder Soleus reports 416,599 shares (4.1%) - Stock Titan
Biodesix Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q3 2025 Biodesix Inc Earnings Call Transcript - GuruFocus
Number of shareholders of Biodesix, Inc. – NASDAQ:BDSX - TradingView
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect? - Yahoo Finance
Biodesix Earnings Call Signals Strong Growth Momentum - The Globe and Mail
Biodesix Faces Mounting Reimbursement and Enforcement Risks as Evolving Payer Policies Threaten Revenue Stability - TipRanks
TD Cowen Maintains Biodesix(BDSX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
MSN Money - MSN
Canaccord Genuity Group Issues Positive Forecast for Biodesix (NASDAQ:BDSX) Stock Price - MarketBeat
Biodesix touts ‘clear path toward profitability’ - BizWest
William Blair Maintains Biodesix(BDSX.US) With Buy Rating - Moomoo
Lake Street Maintains Biodesix(BDSX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
CCORF Maintains Biodesix(BDSX.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Biodesix Inc. 10-Q Q1 2026: Financial Statements, Risk Factors, and Management Analysis - Minichart
Biodesix stock price target raised to $22 by Canaccord on revenue growth - Investing.com
Biodesix, Inc. (NASDAQ:BDSX) Q1 2026 Earnings Call Transcript - Insider Monkey
Biodesix (BDSX) Q1 2026 Earnings Transcript - AOL.com
Biodesix, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Biodesix Q1 Earnings Call Highlights - MarketBeat
BDSX Financials: Income Statement, Balance Sheet & Cash Flow | BIODESIX INC - Stock Titan
BDSX: Q1 revenue up 42% year-over-year, with raised 2026 guidance and margin expansion - TradingView
Biodesix Q1 2026 Earnings Call: Complete Transcript - Benzinga
Earnings call transcript: Biodesix Q1 2026 shows revenue growth, stock steady - Investing.com
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Biodesix Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Biodesix Inc (NASDAQ:BDSX) Q1 Results Smash Estimates, Shares Jump on Raised Guidance - ChartMill
Biodesix (NASDAQ:BDSX) Announces Earnings Results, Beats Estimates By $0.32 EPS - MarketBeat
Q1 2026 Biodesix Inc Earnings Call Transcript - GuruFocus
바이오데식스 (BDSX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오데식스 주식 (BDSX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| O'Kane Kieran | Chief Commercial Officer |
Feb 23 '26 |
Sale |
12.78 |
535 |
6,835 |
9,819 |
| Cowie Robin Harper | CFO, Sec'y & Treasurer |
Feb 23 '26 |
Sale |
12.78 |
535 |
6,835 |
16,231 |
| Vazquez Chris | Chief Accounting Officer |
Feb 23 '26 |
Sale |
12.78 |
211 |
2,696 |
1,586 |
| Hutton Scott | President & CEO |
Feb 23 '26 |
Sale |
12.78 |
1,490 |
19,036 |
48,767 |
0.23%
0.65%
자본화:
|
볼륨(24시간):